Siemens lands FDA clearance for Mammomat Revelation

Siemens Healthineers has received U.S. Food and Drug Administration (FDA) clearance for Mammomat Revelation, the firm's new flagship digital mammography system.

First introduced at RSNA 2017, Mammomat Revelation features the company's InSpect integrated specimen imaging tool for imaging and real-time review of biopsy samples at the workstation, according to Siemens. In addition, Revelation supports digital breast tomosynthesis (DBT) with a wide 50° arc of the system's x-ray tube head. This wide angle also serves as the basis for Revelation's HD Breast Biopsy capability, which is designed to provide one-click targeting of suspicious areas with an accuracy of ± 1 mm, Siemens said.

In other features, Revelation provides automated breast density measurements via its Personalized Soft Compression capability, in which the breast compression process is softened and the compression force is automatically and individually adjusted. The system also supports functional breast imaging with its titanium filter contrast-enhanced mammography mode, which enables users to acquire functional information with morphological detail, according to the company.